Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
23 October 2019 | Story Valentino Ndaba | Photo Valentino Ndaba
Dr Patience book
From left: Prof Melanie Walker (SARChI Chair and Director of Higher Education and Human Development Research Group), Dr Patience Mukwambo (author of the monograph), and Dr Mikateko Hoppener, Senior Researcher in the group.
“A quality higher-education learning experience is a transformative experience for both students and lecturers who develop their minds in criticality, as well as social and self-identity, in addition to other skills and competencies.” This was the message from Dr Patience Mukwambo at the launch of her recently published book – ‘Quality in Higher Education as a Tool for Human Development: Enhancing Teaching and Learning in Zimbabwe’.

The book is a product of her doctoral research and was launched by the office of the SARChI Chair in Higher Education and Human Development, where Dr Mukwambo is a full-time researcher and was introduced at an event held at the Bloemfontein campus of the University of the Free State (UFS) on 21 October 2019. 

Depressing higher-education system

Dr Mukwambo was joined in conversation by Prof Brian Raftopoulos, a Mellon Senior Research Mentor in the Centre for Humanities Research at University of the Western Cape. 

Both scholars testified to the concept of critical thinking, alluding to the depressing state of education in Zimbabwe due to limitations posed by a non-expanding economy and a repressive political space. 

Prof Raftopoulos told the audience the idea of critical thinking has a long genealogy in radical thought which has deepened its roots in modern-day society. 

“What you have seen through the introduction of STEM (Science, Technology, Engineering, and Mathematics), is the increasing idea of functionalising education for a work economy. More often than not, you will hear the state saying it is up to school-leavers to create their own jobs,” said Prof Raftopoulos. According to Dr Mukwambo, part of the challenge is that “critical thinking is omitted on purpose and therefore universities lack a moral compass to work from”.

“While the broader economy might be constraining there are opportunities to develop critical thinking in the classroom, although it might not be uniform across all universities,” said Dr Mukwambo.

Equipping graduates with critical-thinking skills contributes to a range of benefits, such as improved wellbeing, economic outcomes, political engagement, and human capital formation. Quality in teaching and learning is therefore indeed a step in the right direction, towards social justice.


News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept